Rycef S 500 mg/500 mg Injection

Rycef S 500 mg/500 mg Injection is a combination medicine. It is prescribed to treat various types of bacterial infections. It fights against the microorganisms to prevent their growth and further spread of the infection.

Rycef S 500 mg/500 mg Injection should only be administered under the supervision of a healthcare professional. Do not miss any scheduled appointments for taking this medicine. The course of the treatment must be completed even if you feel better. Sudden discontinuation of the treatment may affect the potency of the medicine.

Some common side effects of this medicine are nausea, vomiting, diarrhea, indigestion, etc. If any of the side effects get aggravated, you must consult your doctor immediately. If you experience any allergic reaction (rashes, itching, swelling, shortness of breath, etc.), you must seek immediate medical help.

Before taking this medicine, you should tell your doctor if you are taking any medicines for any health condition. Pregnant or breastfeeding women should also consult with their doctor before taking it. Avoid drinking alcohol as it can cause excessive drowsiness with this medicine. It usually does not impair your ability to drive, but you should not drive if it makes you feel sleepy or dizzy. You must take adequate rest for a faster recovery, also take a healthy diet and drink plenty of water. Your doctor may ask for a few laboratory and diagnostic tests to know the effects of the medicine on your body.

• Treatment of Bacterial infections

Treatment of Bacterial infections
Rycef S 500 mg/500 mg Injection is used to treat bacterial infections like pneumonia, bronchitis, gonorrhea, meningitis, and severe infections of the kidney, urinary system, bones, joints, and skin. It may also be used before surgery, and during and after a cesarean section, in order to prevent the patient from getting an infection. It stops the growth of bacteria causing infection. This further reduces the discomforts associated with various infections and helps in early recovery.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Omtax SB

• Injection site reactions (pain, swelling, redness)
• Injection site pain

Severe side effects of Omtax SB

• Erythema multiforme
• Stevens-Johnson syndrome
• Toxic epidermal necrolysis
• Bone marrow failure
• Anaphylactic reaction

Your doctor or nurse will give you this medicine. Kindly do not self administer.

Rycef S 500 mg/500 mg Injection is a combination of two medicines: Cefotaxime and Sulbactam. Cefotaxime is an antibiotic. It works by preventing the formation of the bacterial protective covering which is essential for the survival of bacteria. Sulbactam is a beta-lactamase inhibitor which reduces resistance and enhances the activity of Cefotaxime against bacteria.

• You have been prescribed this combination medicine to treat bacterial infections even if they have developed resistance.
• Finish the prescribed course, even if you start to feel better. Stopping it early may make the infection come back and harder to treat.
• Diarrhea may occur as a side effect. Taking probiotics along with Rycef S 500 mg/500 mg Injection may help. Talk to your doctor if you notice bloody stools or develop abdominal cramps.
• Stop taking Rycef S 500 mg/500 mg Injection and inform your doctor immediately if you develop an itchy rash, swelling of the face, throat or tongue or breathing difficulties while taking it.

Chambers HF, Deck DH. Beta-Lactam & Other Cell Wall- & Menbrane-Active Antibiotics. In: Katzung BG, Masters SB, Trevor AJ (Editors). Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 773-793.

Petri, Jr WA. Penicillins, Cephalosporins, and Other β-Lactam Antibiotics. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 11th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1127-1154.